Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0JU4R
|
|||
| Drug Name |
Thiazole derivative 4
|
|||
| Synonyms |
PMID28270010-Compound-Figure15-b
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
ARRAY BIOPHARMA INC
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H20F3N7OS
|
|||
| Canonical SMILES |
CC1=C(N(N=C1C2=CN(N=C2)C)C3=CC=CC=C3)NC(=O)NC4=C(N=C(S4)C(F)(F)F)C5=CC=CC=C5
|
|||
| InChI |
1S/C25H20F3N7OS/c1-15-19(17-13-29-34(2)14-17)33-35(18-11-7-4-8-12-18)21(15)31-24(36)32-22-20(16-9-5-3-6-10-16)30-23(37-22)25(26,27)28/h3-14H,1-2H3,(H2,31,32,36)
|
|||
| InChIKey |
OKQYVMVRBRSVES-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tropomyosin-related kinase A (TrkA) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tropomyosin-related kinase A (TrkA) | Target's Patent Info | [1] | |
| KEGG Pathway | MAPK signaling pathway | |||
| Endocytosis | ||||
| Apoptosis | ||||
| Neurotrophin signaling pathway | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Pathways in cancer | ||||
| Transcriptional misregulation in cancer | ||||
| Thyroid cancer | ||||
| Central carbon metabolism in cancer | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Neurotrophic factor-mediated Trk receptor signaling | |||
| Reactome | Frs2-mediated activation | |||
| ARMS-mediated activation | ||||
| NGF-independant TRKA activation | ||||
| PI3K/AKT activation | ||||
| WikiPathways | MAPK Signaling Pathway | |||
| BDNF signaling pathway | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| NGF signalling via TRKA from the plasma membrane | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.